L&C BIO Co.,LTD (KOSDAQ:290650)

L&C BIO Co.,LTD Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 16, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,356,377	546,706	657,862	524,021	830,267	754,757
Market Cap Growth	162.25%	-16.90%	25.54%	-36.88%	10.01%	300.62%
Enterprise Value	1,419,484	613,095	657,447	594,079	823,218	740,027
Last Close Price	54600.00	24080.75	28911.57	22950.56	36285.69	34155.55
PE Ratio	17.74	3.88	13.60	115.32	60.10	69.80
Forward PE	-	71.84	71.84	71.84	71.84	84.66
PS Ratio	16.96	7.58	9.98	9.97	18.18	22.89
PB Ratio	5.09	1.86	4.19	4.86	8.90	12.32
P/TBV Ratio	24.21	6.42	4.52	5.55	9.90	13.11
P/FCF Ratio	4056.70	-	-	-	1266.25	171.43
P/OCF Ratio	197.79	-	-	-	76.13	101.73
EV/Sales Ratio	17.75	8.50	9.97	11.30	18.02	22.44
EV/EBITDA Ratio	189.27	65.95	47.70	42.46	51.22	83.04
EV/EBIT Ratio	-	241.18	80.87	62.64	62.51	101.04
EV/FCF Ratio	4245.44	-	-	-	1255.50	168.08
Debt / Equity Ratio	0.35	0.42	0.52	0.76	0.07	0.25
Debt / EBITDA Ratio	12.58	13.33	5.96	5.86	0.43	1.69
Debt / FCF Ratio	282.13	-	-	-	10.42	3.41
Asset Turnover	0.21	0.20	0.28	0.34	0.49	0.45
Inventory Turnover	0.82	0.78	0.80	1.10	1.69	1.87
Quick Ratio	0.32	0.49	0.77	1.37	5.77	9.97
Current Ratio	0.70	0.84	1.28	3.43	8.45	12.38
Return on Equity (ROE)	37.20%	63.44%	36.92%	5.66%	20.17%	19.99%
Return on Assets (ROA)	0.02%	0.43%	2.20%	3.86%	8.76%	6.24%
Return on Invested Capital (ROIC)	0.03%	0.48%	2.37%	4.09%	9.33%	6.62%
Return on Capital Employed (ROCE)	0.00%	0.80%	5.10%	5.20%	12.90%	9.50%
Earnings Yield	5.75%	25.80%	7.35%	0.87%	1.66%	1.43%
FCF Yield	0.02%	-2.43%	-5.57%	-8.32%	0.08%	0.58%
Dividend Yield	0.09%	0.21%	-	-	-	-
Payout Ratio	1.44%	1.61%	2.31%	24.54%	7.80%	6.74%
Buyback Yield / Dilution	-14.05%	-1.90%	-8.98%	-1.74%	-1.83%	0.33%
Total Shareholder Return	-13.96%	-1.69%	-8.98%	-1.74%	-1.83%	0.33%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.